News

Celcuity Announces Upcoming Presentation at Major Symposium

Celcuity Announces Upcoming Presentation at Major Symposium

Celcuity to Share Important Findings at Upcoming Symposium

Celcuity Inc. is set to present updated data from its PIK3CA Wild-Type cohort as part of the Phase 3 VIKTORIA-1 clinical trial at a major breast cancer symposium. This annual event, which will take place both virtually and in person, offers an incredible platform for sharing pivotal research findings and advancements in oncology.

Essentials of the Presentation

The abstract detailing these findings has been accepted for an oral presentation session. This will encompass important subgroup efficacy analyses and safety data regarding the use of gedatolisib, a multi-target inhibitor aimed at treating HR+/HER2-/PIK3CA wild-type advanced breast cancer. The presentation is scheduled for December 11, and it features vital insights into recent developments in treatment protocols.

Abstract Details

Abstract Title: Gedatolisib combined with fulvestrant, with or without palbociclib, for second-line treatment in patients dealing with HR+/HER2-/PIK3CA WT advanced breast cancer: updated results from randomized Phase 3 VIKTORIA-1. The session will carry presentation number RF7-04, further enriching the discussions at this symposium.

About Celcuity Inc.

Celcuity Inc., headquartered in Minneapolis, is a dynamic clinical-stage biotechnology company committed to developing targeted therapies to address various solid tumor indications. Its leading therapeutic candidate, gedatolisib, effectively acts as a pan-PI3K and mTORC1/2 inhibitor, serving to hinder the PI3K/AKT/mTOR pathway comprehensively.

Clinical Trials and Future Directions

The efficacy of gedatolisib will be demonstrated through ongoing clinical trials, including VIKTORIA-1, which recently completed enrollment. This study explores the drug's potential when combined with other therapeutic agents such as fulvestrant and palbociclib. Additionally, the VIKTORIA-2 trial is underway, investigating gedatolisib combined with a CDK4/6 inhibitor and fulvestrant as an initial treatment option for patients with HR+/HER2- advanced breast cancer.

Further Information and Updates

Moreover, Celcuity continues to push boundaries in the treatment of metastatic castration-resistant prostate cancer through the ongoing Phase 1/2 clinical trial, CELC-G-201. The company is eager to share updates on both current progress and future research directions as they evolve.

Staying Informed

For additional insights into Celcuity’s active clinical trials, stakeholders and interested parties are encouraged to explore their comprehensive listings on ClinicalTrials.gov. The information will illuminate the potential impacts of their innovative therapies on oncology.

Frequently Asked Questions

What is the main purpose of the presentation at the symposium?

The presentation will share significant updates regarding the efficacy and safety of gedatolisib in treating advanced breast cancer patients.

When is the presentation scheduled?

The oral presentation is scheduled for December 11.

What is Celcuity's primary drug?

Celcuity’s leading drug candidate is gedatolisib, a pan-PI3K and mTORC1/2 inhibitor.

What types of cancer does Celcuity focus on?

Celcuity specializes in targeting solid tumors, including advanced breast cancer and metastatic castration-resistant prostate cancer.

How can I find out more about Celcuity's research?

Comprehensive clinical trial information is available on ClinicalTrials.gov and Celcuity’s official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Steel Dynamics Gears Up for Q3 2026 Earnings Update

Updated Category News Views 5

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Continue Reading
Aspen Dental Brings Comprehensive Care to Whiteville

Updated Category News Views 5

Bringing Dentistry Closer to Home Now, Whiteville's dental game just got a power-up, with Aspen Dental setting up shop in town. This isn't just another practice popping up—it's a full-on dental hub offering everything from regular cleanings to emergency tooth fixes. And let’s face it, this area's diverse population needs it. The Man Behind the Chair Guess who’s at...

Continue Reading
PrideStaff: 8 Years Strong on Franchise Times Top 400

Updated Category News Views 4

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Continue Reading
Protecting Your Family on Halloween: Safety Tips

Updated Category News Views 5

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Continue Reading
Teamsters Secure Landmark Deal for SF Parking Workers

Updated Category News Views 4

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...

Continue Reading
Raken Debuts Change Orders: A Game-Changer for Builds

Updated Category News Views 3

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

Continue Reading
Hexaware Teams with Anthropic for Game-Changing AI Move

Updated Category News Views 4

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

Continue Reading
Webull Faces Legal Scrutiny Over Chinese Ties

Updated Category News Views 4

The Unfolding Drama for Webull Shareholders When you see a ticker like NASDAQ:BULL rolling off your tongue these days, it’s not just about stock prices anymore—it's a whole saga wrapped in legal and geopolitical spice. Following the recent uproar from a House China committee report, Webull found itself thrust into the spotlight for all the wrong reasons. That report...

Continue Reading
Rutter Mills Secures $13M in Virginia Injury Cases

Updated Category News Views 4

The Stakes in Virginia When you drop nine successful injury cases on the scales and they tip over $13 million, that's a story worth dissecting. The two top dogs at Rutter Mills certainly know how to make a splash in the legal puddle, don't they? We're talking about attorneys Adam H. Lotkin and Georgina D. Montgomery here, the legal eagles behind these jaw-dropping...

Continue Reading
Lupin Secures FDA Nod for Key Injectable Drug

Updated Category News Views 4

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

Continue Reading

Top 5 Most Recently Viewed Articles

Ocean Biomedical Secures Patent for Innovative Cancer Treatment

Updated Category News Views 102

Ocean Biomedical Secures Significant Patent Grant Ocean Biomedical, Inc. (NASDAQ: OCEA), a leading biopharmaceutical company, has recently achieved a momentous milestone by securing a patent grant for its groundbreaking bispecific antibodies targeting CHI3L1 and PD1. This innovative treatment is designed to enhance T cell-mediated cytotoxicity against tumor cells and is...

Continue Reading
Key Resolutions from AB Amber Grid's Shareholders Meeting

Updated Category News Views 130

Decisions Made During the Shareholders Meeting of AB Amber Grid AB Amber Grid, recognized with the legal entity code 303090867, is headquartered at Laisv?s ave. 10, LT-04215. Recently, the company convened for an important Ordinary General Meeting of Shareholders where some pivotal decisions were made regarding its financial direction and governance. Auditor's Report...

Continue Reading
Discover Fast Cash Solutions for Homeowners at Liz Buys Houses

Updated Category News Views 316

Introducing a Simple Way to Sell Your Home for Cash In today's fast-paced real estate market, homeowners often find themselves needing to sell their properties quickly and without the burden of traditional sales processes. This is where Liz Buys Houses steps in with their innovative service, 'We Buy Houses For Cash!'. This service caters specifically to homeowners who...

Continue Reading
Torani Marks 100 Years with Flavor Innovations and Community Grants

Updated Category News Views 668

Torani Celebrates a Century of Flavor Excellence Torani, a celebrated name in the world of flavors, is proudly marking its 100th anniversary, embracing its rich legacy and the innovative spirit that has made it a household name. With roots tracing back to a small mom-and-pop shop that started with just five flavored syrups, it has now burgeoned into a global sensation...

Continue Reading
Black Hills Corp Reports Strong Earnings for 2025 Q2

Updated Category News Views 146

Black Hills Corp Earnings Report Highlights It's an exciting time for Black Hills Corp (NYSE: BKH) as they reaffirm their 2025 earnings guidance, estimating earnings per share in the range of $4.00 to $4.20. The company's recent second-quarter results illustrate their commitment to growth and operational excellence. Financial Performance Overview In the financial results...

Continue Reading